SU175622A1 - ANTICOAGULANT MEANS - Google Patents
ANTICOAGULANT MEANSInfo
- Publication number
- SU175622A1 SU175622A1 SU820179A SU820179A SU175622A1 SU 175622 A1 SU175622 A1 SU 175622A1 SU 820179 A SU820179 A SU 820179A SU 820179 A SU820179 A SU 820179A SU 175622 A1 SU175622 A1 SU 175622A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- nafarin
- anticoagulant means
- anticoagulant
- oxycoumarin
- phenyl
- Prior art date
Links
- 230000002429 anti-coagulation Effects 0.000 title description 2
- 239000003146 anticoagulant agent Substances 0.000 title description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N Dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 102100015239 F2 Human genes 0.000 description 1
- 229940039716 Prothrombin Drugs 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
Description
Известны различные антикоагул нтные средства , например дикумарин и неодикумарнн.Various anticoagulants are known, for example, Dicoumarin and Neodicmarnn.
В качестве средства дл профилактики и лечени тромбоэмболических заболеваний предлагаетс примен ть 3-(а-фенил-р-метилацетилэтил ) -4-оксикумарин-1Ма (нафарин).As a means for the prevention and treatment of thromboembolic diseases, 3- (a-phenyl-p-methyl-acetyl-ethyl) -4-oxycoumarin-1Ma (nafarin) is proposed.
Нафарин снижает уровень протромбина в крови на 40-60% уже в дозе 1 мг/кг при введении через рот, внутривенно или внутримышечно . Максимум эффекта наступает через 24-48 час после введени и продолжаетс 3-4 дн . Последующее ежедневное или через день введение препарата в меньших дозахNafarin reduces the level of prothrombin in the blood by 40-60% already at a dose of 1 mg / kg when administered orally, intravenously or intramuscularly. The maximum effect occurs 24-48 hours after administration and lasts 3-4 days. Subsequent daily or every other day the introduction of the drug in smaller doses
(0,05-0,1 мг/кг) позвол ет поддерживать необходимый уровень снижени свертывани крови.(0.05-0.1 mg / kg) allows maintaining the required level of blood coagulation reduction.
Нафарин мало токсичен и в примен емых дозах но данным гистологических исследований не вызывает побочных осложнений.Nafarin is slightly toxic and in applied doses, but according to histological studies, it does not cause side complications.
Предмет изобретени Subject invention
Применение3- (а-фенил-р-метилацетилэтил )-4-оксикумарин- Ма (нафарин) в качестве средства дл профилактики и лечени тромбоэмболических заболеваний.The use of 3- (a-phenyl-p-methyl-acetyl ethyl) -4-oxycoumarin-ma (nafarin) as a means for the prevention and treatment of thromboembolic diseases.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU175622A1 true SU175622A1 (en) |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525599A1 (en) * | 1982-04-26 | 1983-10-28 | Mo Khim T | Alcohol complexes of 4-oxo-coumarin derivs. - are anticoagulants of low toxicity, forming stable aq solns. suitable for injection |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525599A1 (en) * | 1982-04-26 | 1983-10-28 | Mo Khim T | Alcohol complexes of 4-oxo-coumarin derivs. - are anticoagulants of low toxicity, forming stable aq solns. suitable for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3245654B2 (en) | Stable extract of Hypericum perforatum, its preparation method and pharmaceutical composition | |
| JPS60109522A (en) | Bilobalid-containing medicine composition for treating neurosis | |
| HU197840B (en) | Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin | |
| AU2006325947B2 (en) | Agent for prevention and treatment of acute renal failure | |
| JPH10510241A (en) | Use of ketoconazole and related substances as a therapeutic agent for type II diabetes | |
| SU175622A1 (en) | ANTICOAGULANT MEANS | |
| JPH0352815A (en) | Remedy for intravascular blood coagulation syndrome | |
| US5905069A (en) | Methods of decreasing or preventing pain using spicamycin or derivatives thereof | |
| AU714086B2 (en) | Use of COMT inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions | |
| EP0207505A2 (en) | Use of a prenyl ketone in the preparation of a medicament against gastritis | |
| EP0670721A1 (en) | Drug for treatment and prophylaxis of bone and joint diseases | |
| US4156003A (en) | Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine | |
| CA2551043A1 (en) | The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases | |
| NZ239601A (en) | Use of n-acetyl neuraminic acid for treating kidney diseases | |
| JPH0522687B2 (en) | ||
| KR100198490B1 (en) | Pharmaceutical compositions for treating liver disease | |
| RU2257896C2 (en) | Method for anesthesia at short-term laser-surgical interferences in the field of ophthalmology | |
| JP2816499B2 (en) | Diabetes treatment | |
| US4128661A (en) | (Bis-diethylamine)2,5-dihydroxybenzene-1,4-disulfonate, useful as a medicament against glaucoma | |
| Bruce-Chwatt et al. | Chloroquine naphthoate for malaria | |
| Joseph et al. | Listerial Meningitis | |
| Walker | Poliomyelitis Vaccine | |
| MXPA99005706A (en) | Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions | |
| GRANINGER et al. | Pharmaeokineties of Telithromycin in Plasma and Soft Tissues after Single Dose Administration to Healthy Volunteers | |
| London | LJ BRUCE-CHWATT. |